A SINGLE ARM, MULTICENTER, PHASE II, OPEN-LABEL TRIAL TO EVALUATE EFFICACY OF ISATUXIMAB IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE
Study of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS)
Sponsor: Sanofi Genzyme
Enrolling: Male and Female Patients
IRB Number: AAAT0761
U.S. Govt. ID: NCT04614558
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with Monoclonal Gammopathy of Renal Significance (MGRS). Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat Monoclonal Gammopathy of Renal Significance (MGRS). This means that the use of isatuximab in this study is considered investigational.
Investigator
Divaya Bhutani, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have kidney failure and protein in urine? Yes No
Have you been diagnosed with Monoclonal Gammopathy of Renal Significance (MGRS)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE